[A24-07] Sacituzumab govitecan (breast cancer) – Addendum to Project A23-86
Last updated 15.02.2024
Project no.:
A24-07
Commission:
Commission awarded on 09.01.2024 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adult patients with unresectable or metastatic hormone receptor-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least 2 additional systemic therapies in the advanced setting
After addendum now: proof of considerable added benefit
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
https://dx.doi.org/10.60584/A24-07_en
| Project no. | Title | Status |
|---|---|---|
| A23-86 | Sacituzumab govitecan (breast cancer) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2024-02-15 A G-BA decision was published.